Table 1.

Baseline demographics, disease characteristics, and changes after the 8-week treatment

	Once weekly				Once every 2 weeks
	Placebo	5 mg	10 mg	20 mg	10 mg	20 mg
n	49*	50*	49*	50*	50*	49*
Sex (female/male)	57/43	48/52	39/61	64/36	48/52	55/45
Age (years)	56 ± 6	57 ± 7	56 ± 8	56 ± 8	53 ± 11	56 ± 7
BMI (kg/m2)	31.8 ± 4.9	33.2 ± 5.3	32.6 ± 4.7	32.4 ± 5.2	33.1 ± 5.1	33.2 ± 5.1
Duration of diabetes (years)	5 ± 4	6 ± 6	5 ± 5	5 ± 4	5 ± 4	6 ± 5
Metformin dose (mg/day)	2,019 ± 63	1,897 ± 51	1,888 ± 53	1,998 ± 57	2,011 ± 68	1,934 ± 56
Systolic blood pressure (mmHg)	129 ± 13	127 ± 13	128 ± 14	131 ± 14	132 ± 13	132 ± 13
Diastolic blood pressure (mmHg)	77 ± 9	78 ± 8	78 ± 8	80 ± 9	81 ± 8	81 ± 7
A1C (%)	8.0 ± 0.1	7.9 ± 0.1	7.9 ± 0.1	7.8 ± 0.1	8.0 ± 0.1	7.9 ± 0.1
Δ	−0.2	−1.0	−1.2	−1.2	−0.9	−1.0
P		<0.0001	<0.0001	<0.0001	<0.0001	<0.0001
Fructosamine (μmol/l)	310 ± 6	310 ± 6	300 ± 6	292 ± 6	309 ± 6−	290 ± 6
Δ	−5 ± 4	−44 ± 4	−51 ± 4	−48 ± 4	−35 ± 4	−40 ± 4
P		<0.0001	<0.0001	<0.0001	<0.0001	<0.0001
Fasting glucose (mg/dl)	173 ± 5	187 ± 5	175 ± 5	164 ± 5	175 ± 5	171 ± 5
Δ	−14	−33	−45	−45	−22	−26
P		0.0002	<0.0001	<0.0001	0.13	0.02
Proinsulin-to-insulin ratio	0.590 ± 0.032	0.579 ± 0.032	0.594 ± 0.032	0.550 ± 0.032	0.606 ± 0.031	0.613 ± 0.032
Δ	0.002	−0.079	−0.120	−0.166	−0.091	−0.055
P		0.0738	0.0076	0.0003	0.0372	0.2054
Lipid parameters
Total cholesterol (mg/dl)	211 ± 6	201 ± 6	195 ± 6	194 ± 6	196 ± 6	200 ± 6
Δ	+7	−8	−12	−9	−7	−12
LDL cholesterol (mg/dl)	127 ± 5	117 ± 5	116 ± 5	113 ± 5	114 ± 5	114 ± 5
Δ	+5	−3	−8	+1	−0	−6
HDL cholesterol (mg/dl)	47 ± 2	45 ± 2	45 ± 2	45 ± 2	44 ± 2	43 ± 2
Δ	+0	−1	−2	−1	−1	0
Triglycerides (mg/dl)	224 ± 27	220 ± 27	188 ± 28	199 ± 27	220 ± 27	256 ± 27
Δ	+9	−22	−26	−48	−28	−27

Data are means ± SD for baseline characteristics and mean ± SEM for disease characteristics.